Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Dec 27, 2020; 12(12): 1341-1348
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1341
Published online Dec 27, 2020. doi: 10.4254/wjh.v12.i12.1341
Safety and efficacy of sofosbuvir/velpatasvir/voxilaprevir in post-liver transplant patients with previous direct-acting antiviral failure: Six case reports
Cory Higley, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Christine C Hsu, Coleman Smith, Alexander T. Lalos, Transplant Institute, MedStar Georgetown University Hospital, Washington, DC 20007, United States
Sandeep Nadella, Department of Gastroenterology, Medstar Georgetown University Hospital, Washington, DC 20007, United States
Author contributions: Higley C collected and analyzed the data; Higley C and Nadella S wrote the manuscript; Hsu CC, Smith C, and Lalos AT designed the research study and edited the manuscript; Lalos AT is the guarantor of the article; and all authors issued final approval for the version to be submitted.
Informed consent statement: Informed consent or a substitute of consent was obtained from all patients prior to inclusion in the study.
Conflict-of-interest statement: Smith C has previously received research support from AbbVie, Gilead, Conatus, Allergen, and Genfit. Smith C and Lalos A have been on the speakers bureau for Gilead and AbbVie.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cory Higley, DO, Attending Doctor, Department of Medicine, MedStar Georgetown University Hospital, 3800 Reservoir Rd NW PHC 5, Washington, DC 20007, United States. cory.higley@gunet.georgetown.edu
Received: July 10, 2020
Peer-review started: July 10, 2020
First decision: October 6, 2020
Revised: October 16, 2020
Accepted: October 30, 2020
Article in press: October 30, 2020
Published online: December 27, 2020
Processing time: 160 Days and 17.8 Hours
Peer-review started: July 10, 2020
First decision: October 6, 2020
Revised: October 16, 2020
Accepted: October 30, 2020
Article in press: October 30, 2020
Published online: December 27, 2020
Processing time: 160 Days and 17.8 Hours
Core Tip
Core Tip: There have been limited reports published on the use of sofosb-uvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for the treatment of hepatitis C virus in post-liver transplant patients who had previous direct-acting antiviral failure prior to transplant. Herein, we present what we believe to be the largest case series of SOF/VEL/VOX use in these patients and highlight its efficacy and safety. More so, we discuss potential drug-drug interactions between SOF/VEL/VOX and common immunosuppression regimens.